Compare USNA & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | ANNX |
|---|---|---|
| Founded | 1992 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.9M | 334.1M |
| IPO Year | 1996 | 2020 |
| Metric | USNA | ANNX |
|---|---|---|
| Price | $20.08 | $4.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $36.00 | $16.60 |
| AVG Volume (30 Days) | 174.4K | ★ 3.4M |
| Earning Date | 10-22-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $912,670,000.00 | N/A |
| Revenue This Year | $9.87 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.20 | ★ N/A |
| Revenue Growth | ★ 5.88 | N/A |
| 52 Week Low | $18.48 | $1.29 |
| 52 Week High | $38.85 | $5.66 |
| Indicator | USNA | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 71.13 |
| Support Level | $19.33 | $4.01 |
| Resistance Level | $20.40 | $5.00 |
| Average True Range (ATR) | 0.58 | 0.36 |
| MACD | 0.22 | 0.07 |
| Stochastic Oscillator | 83.55 | 89.17 |
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.